SCHEMBL5481884

SCHEMBL5481884

COc1ccc2c(/C=C3/C(=O)Nc4ccccc43)cn(C)c2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 7/20 0.71
MAP3K5 Q99683 1/20 0.71
MDM2 Q00987 1/20 0.64
SYK P43405 7/20 0.61
NTRK3 Q16288 5/20 0.61
NTRK2 Q16620 5/20 0.61
FCER2 P06734 5/20 0.61
CSNK1A1 P48729 3/20 0.61
PRKD3 O94806 1/20 0.61
ABL1 P00519 1/20 0.61
RET P07949 1/20 0.61
PDGFRB P09619 1/20 0.61
LTK P29376 1/20 0.61
KDR P35968 1/20 0.61
MAP2K2 P36507 1/20 0.61
FLT3 P36888 1/20 0.61
CDK8 P49336 1/20 0.61
CDK7 P50613 1/20 0.61
MAP2K1 Q02750 1/20 0.61
MST1R Q04912 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5481903 1.00 NTRK1 (0.71) NTRK1MAP3K5MDM2SYKNTRK3
SCHEMBL14448940 1.00 NTRK1 (0.71) NTRK1MAP3K5MDM2SYKNTRK3
SCHEMBL5464897 0.91 SYK (0.72) NTRK1MAP3K5MDM2SYKNTRK3
SCHEMBL5464906 0.91 SYK (0.72) NTRK1MAP3K5MDM2SYKNTRK3
SCHEMBL14448833 0.84 NTRK1 (1.00) NTRK1MAP3K5SYKNTRK3NTRK2
SCHEMBL5469776 0.84 NTRK1 (1.00) NTRK1MAP3K5SYKNTRK3NTRK2
SCHEMBL5469785 0.84 NTRK1 (1.00) NTRK1MAP3K5SYKNTRK3NTRK2
SCHEMBL5469713 0.78 MDM2 (1.00) NTRK1MDM2NTRK3NTRK2CSNK1A1
SCHEMBL5472673 0.78 MDM2 (0.81) NTRK1MDM2NTRK3NTRK2CSNK1A1
SCHEMBL14448889 0.78 MDM2 (1.00) NTRK1MDM2NTRK3NTRK2CSNK1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US claimed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP claimed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO claimed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US disclosed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP disclosed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167488-A1 Novel therapeutic use MAG, PMP22, MYT1 NTRK1 175/4885MAP3K5 3047/4885MDM2 4274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.